• High-density lipoprotein cholesterol
• High-sensitivity C-Reactive protein
• Machine learning
• NHANES
• Nomogram
• Stroke

• Antithrombin
• Inflammation
• Inherited antithrombin deficiency
• Markers of inflammation
• NETOSIS

• Adult
• Aged
• Aged, 80 and over
• Female
• Humans
• Male
• Middle Aged
• Young Adult
• Antithrombin Proteins/deficiency
• Antithrombin Proteins/genetics
• Biomarkers/blood
• C-Reactive Protein/analysis
• Complement C3a/analysis
• Inflammation/blood
• Inflammation/complications
• Intercellular Adhesion Molecule-1/blood
• Nucleosomes
• Vascular Cell Adhesion Molecule-1/blood
• von Willebrand Factor
• Venous Thromboembolism/blood
• Venous Thromboembolism/genetics
• Cohort Studies
• Thrombophilia/blood
• Thrombophilia/genetics

• Asia
• inflammatory bowel disease
• venous thromboembolism

• Humans
• Venous Thromboembolism/epidemiology
• Venous Thromboembolism/etiology
• Incidence
• Inflammatory Bowel Diseases/complications
• Inflammatory Bowel Diseases/epidemiology
• Asian People/statistics & numerical data
• Female
• Asia/epidemiology
• Male
• Colitis, Ulcerative/complications
• Risk Factors
• Crohn Disease/complications

• Biologie vasculaire
• Coagulation system
• Immune system
• Immunothrombose
• Immunothrombosis
• Inflammation
• Sepsis
• Système de coagulation
• Système immunitaire
• Thrombose
• Thrombosis
• Vascular biology
• État septique

• Humans
• Blood Coagulation/physiology
• Cardiovascular Diseases/immunology
• Cardiovascular Diseases/physiopathology
• Cardiovascular Diseases/complications
• Thrombosis/immunology
• Thrombosis/physiopathology
• Inflammation/immunology
• Inflammation/physiopathology
• Inflammation/complications
• Immune System/physiology
• Animals

• Angiotensins
• COVID-19
• Genetic variation
• Intensive Care Units
• Survival

• Humans
• COVID-19/genetics
• COVID-19/mortality
• Iran/epidemiology
• Male
• Female
• Peptidyl-Dipeptidase A/genetics
• Middle Aged
• Severity of Illness Index
• Adult
• SARS-CoV-2/genetics
• Polymorphism, Genetic
• Aged
• INDEL Mutation
• Gene Frequency

• LASSO regression
• cross-sectional study
• dietary inflammatory index
• hypertension
• restricted cubic spline
• spatial statistical analysis

• Decision tree
• Hematology
• Hypertension
• Logistic regression

• Adult
• Female
• Humans
• Cohort Studies
• Prospective Studies
• Iran/epidemiology
• Hypertension
• Leukocytes
• Risk Factors

• miR-10b
• non-small cell lung cancer
• plasminogen activator inhibitor 1 (PAI-1)
• soluble urokinase-type plasminogen activator receptor (suPAR)

• Humans
• Carcinoma, Non-Small-Cell Lung/drug therapy
• Carcinoma, Non-Small-Cell Lung/genetics
• Lung Neoplasms/drug therapy
• Lung Neoplasms/genetics
• MicroRNAs/genetics
• Plasminogen Activator Inhibitor 1/genetics
• Prospective Studies
• Receptors, Urokinase Plasminogen Activator/genetics

• Asymmetric dimethyl-l-arginine (ADMA)
• Cyclic guanosine monophosphate (cGMP)
• Endothelial nitric oxide synthase (eNOS)
• Endothelial nitric oxide synthase (eNOS) uncoupling
• Endothelin-1 (ET-1)
• Endothelium
• Inducible nitric oxide synthase (iNOS)
• Intercellular adhesion molecule-1 (ICAM-1)
• Leucine-rich repeat (LRR)- and pyrin domain-containing protein 3 (NLRP3) inflammasome
• Low-density lipoproteins (LDL)
• Nitric oxide (NO)
• Nuclear factor kappa-B (NF-κB)
• Nucleotide binding and oligomerization domain (NOD)
• Obesity
• Oxidized low-density lipoprotein (OxLDL)
• Peroxynitrite
• Plasminogen-activator inhibitor-1 (PAI-1)
• Protein kinase C (PKC)
• Reactive oxygen species (ROS)
• Saturated fatty acids
• Super oxide dismutase (SOD)
• Tumor necrosis factor-alpha (TNF-α)
• Vascular cell adhesion molecule-1 (VCAM-1)
• Vascular endothelial growth factor (VEGF)
• Vasodilatory-stimulated phosphoprotein (VASP)

• Humans
• Obesity/metabolism
• Obesity/physiopathology
• Obesity/drug therapy
• Obesity/complications
• Endothelium, Vascular/physiopathology
• Endothelium, Vascular/metabolism
• Endothelium, Vascular/drug effects
• Animals
• Cardiovascular Diseases/metabolism
• Cardiovascular Diseases/physiopathology
• Cardiovascular Diseases/drug therapy
• Cardiovascular Diseases/etiology
• Adipose Tissue/metabolism
• Adipose Tissue/physiopathology
• Oxidative Stress

• biomarkers
• cardiovascular risk
• micrornas (mirnas)
• natriuretic peptides
• troponins

• data analysis
• design
• dietary inflammation index
• gensini scoring system
• severe CAD
• the financial support for conception

• Coronary artery disease
• Diabetes
• High-sensitivity C-reactive protein
• Outcomes
• Three-vessel disease

• Humans
• Biomarkers
• C-Reactive Protein/analysis
• Coronary Artery Disease/diagnosis
• Diabetes Mellitus, Type 2/complications
• Diabetes Mellitus, Type 2/diagnosis
• Diabetes Mellitus, Type 2/epidemiology
• Myocardial Infarction/epidemiology
• Prognosis
• Risk Factors
• Stroke/epidemiology

• Dalian Medical Science Research Project
• National Natural Science Foundation of China
• Dalian Youth Science and Technology Star Support program

• COVID-19
• acute respiratory distress syndrome
• disseminated intravascular coagulopathy
• extracorporeal membrane oxygenation

• Cardiovascular event
• Corticosteroid
• Pneumonia

• Humans
• Adrenal Cortex Hormones/adverse effects
• Adrenal Cortex Hormones/therapeutic use
• Cardiovascular Diseases/chemically induced
• Cardiovascular Diseases/epidemiology
• Heart Disease Risk Factors
• Pneumonia/drug therapy
• Retrospective Studies
• Hospitalization

• exercise
• hemostasis
• inflammation

• C-reactive protein/albumin ratio
• acute ischemic stroke
• functional outcome
• hemorrhagic transformation
• inflammation
• intravenous thrombolysis
• recombinant tissue plasminogen activator

• fibrin
• fibrinolysis
• flow
• plasminogen
• platelets
• shear
• thrombus

• British Heart Foundation
• National Centre for the Replacement, Refinement and Reduction of Animals in Research

• c-reactive protein
• meta-analysis
• sodium-dependent glucose transporter 2 inhibitor
• type 2 diabetes

• C-Reactive Protein
• Diabetes Mellitus, Type 2/drug therapy
• Glucose Transport Proteins, Facilitative
• Humans
• Hypoglycemic Agents/pharmacology
• Hypoglycemic Agents/therapeutic use
• Sodium
• Sodium-Glucose Transporter 2 Inhibitors/pharmacology
• Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
• Systematic Reviews as Topic

Colony forming unit-Hill’s (CFU-Hill’s) colonies are hematopoietic-derived cells that participate in neovasculogenesis and serve as a biomarker for vascular health. In animals, overexpression of miR-18a-5p was shown to be pro-atherogenic. We had shown that well-controlled type 1 diabetes mellitus (T1DM) is characterized by an inflammatory state, endothelial dysfunction, and reduced number of CFU-Hill’s, a model of subclinical cardiovascular disease (CVD). MERIT study explored the role of miR-18a-5p expression in CFU-Hill’s colonies in T1DM, and the cardioprotective effect of metformin in subclinical CVD. In T1DM, miR-18a-5p was significantly upregulated whereas metformin reduced it to HC levels. MiR-18a-5p was inversely correlated with CFU-Hill’s colonies, CD34+, CD34+CD133+ cells, and positively with IL-10, C-reactive protein, vascular endothelial growth factor-D (VEGF-D), and thrombomodulin. The receiver operating characteristic curve demonstrated, miR-18a-5p as a biomarker of T1DM, and upregulated miR-18a-5p defining subclinical CVD at HbA1c of 44.5 mmol/mol (pre-diabetes). Ingenuity pathway analysis documented miR-18a-5p inhibiting mRNA expression of insulin-like growth factor-1, estrogen receptor-1, hypoxia-inducible factor-1α cellular communication network factor-2, and protein inhibitor of activated STAT 3, whilst metformin upregulated these mRNAs via transforming growth factor beta-1 and VEGF. We confirmed the pro-atherogenic effect of miR-18a-5p in subclinical CVD and identified several target genes for future CVD therapies.

The development of extracorporeal life support technology has added a new dimension to the care of critically ill patients who fail conventional treatment options. Extracorporeal membrane oxygenation (ECMO)—specialized temporary life support for patients with severe cardiac or pulmonary failure—plays a role in bridging the time for organ recovery, transplant, or permanent assistance. The overall patient outcome is dependent on the underlying disease, comorbidities, patient reaction to critical illness, and potential adverse events during ECMO. Moreover, the contact of the blood with the large artificial surface of an extracorporeal system circuit triggers complex inflammatory and coagulation responses. These processes may further lead to endothelial injury and disrupted microcirculation with consequent end-organ dysfunction and the development of adverse events like thromboembolism. Therefore, systemic anticoagulation is considered crucial to alleviate the risk of thrombosis and failure of ECMO circuit components. The gold standard and most used anticoagulant during extracorporeal life support is unfractionated heparin, with all its benefits and disadvantages. However, therapeutic anticoagulation of a critically ill patient carries the risk of clinically relevant bleeding with the potential for permanent injury or death. Similarly, thrombotic events may occur. Therefore, different anticoagulation strategies are employed, while the monitoring and the balance of procoagulant and anticoagulatory factors is of immense importance. This narrative review summarizes the most recent considerations on anticoagulation during ECMO support, with a special focus on anticoagulation monitoring and future directions.

• ACS, acute coronary syndrome
• LT, lysis time
• MACE, major adverse cardiovascular events
• OT, occlusion time
• PAI, plasminogen activator inhibitor
• PCI, percutaneous coronary intervention
• STEMI, ST-segment elevation myocardial infarction
• fibrinolysis
• myocardial infarction
• platelet function
• t-PA, tissue plasminogen activator
• thrombosis
• vWF, von Willebrand factor

Metabolic syndrome (MetS) is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). Antipsychotic (AP)-induced MetS (AIMetS) is the most common adverse drug reaction (ADR) of psychiatric pharmacotherapy. Herein, we review the results of studies of blood (serum and plasma) and urinary biomarkers as predictors of AIMetS in patients with schizophrenia (Sch). We reviewed 1440 studies examining 38 blood and 19 urinary metabolic biomarkers, including urinary indicators involved in the development of AIMetS. Among the results, only positive associations were revealed. However, at present, it should be recognized that there is no consensus on the role of any particular urinary biomarker of AIMetS. Evaluation of urinary biomarkers of the development of MetS and AIMetS, as one of the most common concomitant pathological conditions in the treatment of patients with psychiatric disorders, may provide a key to the development of strategies for personalized prevention and treatment of the condition, which is considered a complication of AP therapy for Sch in clinical practice.

• antipsychotic-induced metabolic syndrome
• antipsychotics
• metabolic syndrome
• personalized metabolomics
• personalized psychiatry
• serum biomarkers
• urinary biomarkers

There is a continuous worldwide increase in incidences of metabolic syndrome (MetS) reaching about a quarter of the world’s population. Thus, studies that allow for a robust diagnosis of MetS are of paramount importance from an economic and medical point of view. This study was carried out in a group of men diagnosed with MetS using consensus definition criteria that included the definitions of the International Diabetes Foundation and Diabetes Federation and the American Heart Association/National Heart, Lung, and Blood Institute. The control group consisted of men for whom the parameters that define the MetS were in the norm. This study analyzed statistical differences between MetS and healthy men and the correlations between the set of 14 potential markers of MetS, that is, between body mass index, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein, triglycerides, cortisol, adiponectin, monocyte chemotactic protein-1 (MCP-1), C-reactive protein (CRP), adipsin, leptin, resistin, and plasminogen activator inhibitor-1 (PAI)-1. This report revealed a significant difference between MetS and healthy men in most of the parameters studied. Furthermore, a strong positive correlation between cortisol levels and body mass index was demonstrated. Furthermore, MCP-1 levels in men with MetS were significantly higher than their levels in healthy men. Finally, a strong positive correlation was also observed between adiponectin and adipsin in Mets men. Thus, this study reveals the potential usefulness of adiponectin, MCP-1, adipsin, leptin, resistin, and PAI-1 as markers of MetS in adult men.

• CRP
• MCP-1
• PAI-1
• adiponectin
• adipsin
• cortisol
• leptin
• markers
• metabolic syndrome
• resistin

Extracorporeal membrane oxygenation (ECMO) is increasingly used in carefully selected patients with cardiac or respiratory failure. However, complications are common and can be associated with worse outcomes, while data on risk factors and outcomes are inconsistent and sparse. Therefore, we sought to investigate potential risk factors and predictors of haemorrhage and adverse events during ECMO and its influence on mortality. We retrospectively reviewed all patients on ECMO support admitted to intensive care units of a tertiary university centre in Austria. In a period of ten years, ECMO support was used in 613 patients, with 321 patients meeting the inclusion criteria of this study. Haemorrhage, occurring in more than one third of the included patients (123, 38%), represented the most common and serious ECMO complication, being associated with an increased one year mortality (51% vs. 35%, p = 0.005). The main risk factors for haemorrhage were severity of the disease (hazard ratio (HR) = 1.01, p = 0.047), a prolonged activated partial thromboplastin time (HR = 1.01, p = 0.007), and lower values of C-reactive protein (HR = 0.96, p = 0.005) and procalcitonin (HR = 0.99, p = 0.029). In summary, haemorrhage remained the main ECMO complication with increased mortality. Moreover, we reported a possible association of lower inflammation and bleeding during ECMO support for the first time. This generated a new hypothesis that warrants further research. Finally, we recommend stricter monitoring of anticoagulation especially in patients without hyperinflammation.

• ECMO
• aPTT
• anticoagulation
• bleeding
• complications
• extracorporeal life support
• inflammation
• mortality

This study aimed to investigate the impact of anaemia on long-term clinical outcomes in patients who underwent semi-urgent and elective percutaneous coronary intervention (PCI) in an Asian population. Although the effects of anaemia on outcomes in Asian patients are well studied for acute coronary syndrome, its impact on Asian patients undergoing semi-urgent and elective PCI is unclear.

This was a retrospective cohort study of patients who underwent semi-urgent and elective PCI from January 1, 2014, to December 31, 2015, at a tertiary academic centre. A total of 1,685 patients were included. They were stratified into three groups: normal (≥12 g/dL), intermediate (10–11.9 g/dL), and low (<10 g/dL) haemoglobin levels. Demographics, risk factors, and end-points including the 5-point major adverse cardiac and cerebrovascular events (MACCE) (all-cause death, subsequent stroke, myocardial infarction, congestive cardiac failure, and target lesion revascularisation), cardiovascular death, and bleeding events were analysed.

Patients in intermediate and low haemoglobin level groups were older with more comorbidities. Compared to the normal haemoglobin level group, low haemoglobin level group patients were associated with an increased risk of composite endpoints of all-cause death, subsequent stroke, myocardial infarction, congestive cardiac failure, and target lesion revascularisation [adjusted hazard ratio (aHR) 1.89, 95% confidence interval (CI):1.22, 2.92; p = 0.004]. This was driven by the increased risk of target lesions revascularisation observed in the low haemoglobin level group compared to the normal haemoglobin level group (aHR 17.74, 95% CI: 1.74, 180.80; p = 0.015). The patients in the low haemoglobin level group were also associated with a higher risk of bleeding events compared to the normal haemoglobin level group (aHR 7.18, 95% CI: 1.13, 45.40; p = 0.036).

In our Asian cohort, patients with anaemia undergoing PCI were associated with a higher comorbid burden. Despite adjustments for comorbidities, these patients had higher mortality and worse cardiovascular outcomes following contemporary PCI.

• cancer
• cancer survivors
• cancer treatment-related cardiotoxicity
• cardio-oncology
• cardiovascular disease (CVD)
• conceptual framework
• greenspace
• inflammation
• major adverse cardiovascular events (MACEs)
• socioecological model of health

• Cancer Survivors
• Cardiovascular Diseases/etiology
• Cardiovascular System
• Humans
• Inflammation/complications
• Neoplasms/complications
• Neoplasms/epidemiology
• Parks, Recreational

• R01HL133029 NIH HHS
• R01CA214805 NIH HHS

• inflammation
• innate immunity
• tissue-type plasminogen activator
• uPAR
• urokinase-type plasminogen activator

• C-reactive protein
• Men
• Mortality
• Systolic blood pressure

• Adult
• Age Factors
• Biomarkers/blood
• Blood Pressure
• C-Reactive Protein/analysis
• Cause of Death
• Coronary Disease/blood
• Coronary Disease/diagnosis
• Coronary Disease/mortality
• Coronary Disease/physiopathology
• Finland/epidemiology
• Heart Disease Risk Factors
• Humans
• Hypertension/blood
• Hypertension/diagnosis
• Hypertension/mortality
• Hypertension/physiopathology
• Inflammation/blood
• Inflammation/diagnosis
• Inflammation/mortality
• Inflammation/physiopathology
• Inflammation Mediators/blood
• Male
• Middle Aged
• Prognosis
• Prospective Studies
• Risk Assessment
• Sex Factors
• Time Factors

Atherosclerosis is considered a disease caused by a chronic inflammation, associated with endothelial dysfunction, and several mediators of inflammation are up-regulated in subjects with atherosclerotic disease. Healthy, intact endothelium exhibits an antithrombotic, protective surface between the vascular lumen and vascular smooth muscle cells in the vessel wall. Oxidative stress is an imbalance between anti- and prooxidants, with a subsequent increase of reactive oxygen species, leading to tissue damage. The renin-angiotensin-aldosterone system is of vital importance in the pathobiology of vascular disease. Convincing data indicate that angiotensin II accelerates hypertension and augments the production of reactive oxygen species. This leads to the generation of a proinflammatory phenotype in human endothelial and vascular smooth muscle cells by the up-regulation of adhesion molecules, chemokines and cytokines. In addition, angiotensin II also seems to increase thrombin generation, possibly via a direct impact on tissue factor. However, the mechanism of cross-talk between inflammation and haemostasis can also contribute to prothrombotic states in inflammatory environments. Thus, blocking of the renin-angiotensin-aldosterone system might be an approach to reduce both inflammatory and thrombotic complications in high-risk patients. During COVID-19, the renin-angiotensin-aldosterone system may be activated. The levels of angiotensin II could contribute to the ongoing inflammation, which might result in a cytokine storm, a complication that significantly impairs prognosis. At the outbreak of COVID-19 concerns were raised about the use of angiotensin converting enzyme inhibitors and angiotensin receptor blocker drugs in patients with COVID-19 and hypertension or other cardiovascular comorbidities. However, the present evidence is in favor of continuing to use of these drugs. Based on experimental evidence, blocking the renin-angiotensin-aldosterone system might even exert a potentially protective influence in the setting of COVID-19.

• angiotensin II
• antihypertensive treatment
• coagulation
• haemostasis
• hypertension
• renin-angiotensin-aldosterone system

• Arthritis, Rheumatoid
• Atherosclerosis
• Cardiovascular Diseases
• Inflammation

• PAI-1
• diabetes
• fibrinolysis
• inflammation
• metabolic syndrome
• obese
• thrombosis

• Acute ischemic stroke
• C-reactive protein
• Intravenous thrombolysis
• Outcome

• adiponectin
• hs CRP
• metabolic syndrome
• tempe gembus

Many specific and non-specific electrocardiographic abnormalities including ventricular arrhythmias have been reported in subjects with sickle cell anemia (SCA). In SCA patients, cardiac electrical abnormalities may be the leading cause of increased risk of arrhythmias. The corrected QT (QTc) interval, peak to the end of the T wave (Tp-e) interval and associated Tp-e/QTc ratio are promising measures of altered ventricular repolarization and increased arrhythmogenesis risk.

This study assessed ventricular repolarization abnormalities in subjects with SCA using the QTc interval, Tp-e interval and Tp-e/QTc ratio, and also evaluated the gender differences in these parameters, as well as their determinants.

Sixty subjects with SCA and 60 healthy control subjects, matched for age and gender, were studied. All participants underwent physical examination, hematological and biochemical evaluation, and 12-lead electrocardiography (ECG) recording. QT and Tp-e intervals were measured from the ECG, and the QTc interval was calculated using Bazett’s formula. Tp-e/QT and Tp-e/QTc ratios were also derived.

QT and QTc intervals were prolonged in subjects with SCA. Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio were prolonged in male SCA subjects, with a paradoxical shortening in female SCA subjects. Plasminogen activator inhibitor-1 (PAI-1) was an independent determinant of QTc, while body mass index (BMI) was an independent determinant of both Tp-e interval and Tp-e/QTc ratio.

Our results suggest an elevated risk for ventricular arrhythmogenesis in male SCA subjects. Furthermore, increased BMI and PAI-1 level are possible markers of ventricular repolarization abnormalities in SCA subjects.

• QTc interval
• Tp-e interval
• arrhythmias
• electrocardiography
• sickle cell anemia
• ventricular repolarization

• C-reactive protein
• Men
• Sudden cardiac death
• Systolic blood pressure

To review the latest progress on the pathogenic mechanism and management of rheumatoid arthritis (RA)-associated coronary artery disease (CAD), and propose advice on future management optimization as well as prospects for research and development of new therapeutic regimen.

This study was based on data obtained from PubMed up to May 2019 using various search terms and their combinations, including coronary artery disease, myocardial ischemia, cardiovascular diseases, RA, rheumatic diseases, treatment, therapy, strategies, immunotherapy, inflammation, and anti-inflammation.

All retrieved literature was scrutinized, most relevant articles about the pathogenic mechanism and clinical management, especially anti-inflammatory therapy of RA-associated CAD were reviewed.

RA is an immune-mediated chronic inflammatory disease which has a great social disease burden. In addition to typical arthritic manifestations, RA also affects extra-articular tissues and organs, within which the involvement of the cardiovascular system, especially incorporating CAD, is the leading cause of death for patients with RA. Recently, numerous basic and clinical studies have been carried out on the mechanism of CAD development and progression under the inflammatory cascade of RA. The effect of traditional RA drugs on CAD risk management has been gradually clarified, and more emerging biologic agents are being explored and studied, which have also achieved satisfactory outcomes. Furthermore, with the success of the CANTOS clinical trial, novel anti-inflammatory therapy for the prevention of cardiovascular disease is believed to have a broad prospect.

RA is an independent risk factor for CAD, which mainly results from the underlying inflammatory cascade; therefore, anti-inflammatory therapy, especially the emerging novel biologic drugs, is important for CAD management in patients with RA and may also be a promising approach among the general population.